News archives 2021.08

Home > 2021.08

2021.08.24

Closing of the Series C funding to advance pipeline of novel GPCR antibodies

NBHL has closed the Series C funding to advance pipeline of novel GPCR antibodies.

Click here for detail.

Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies

NBHL has singed the Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies.

Click here for details.